放化疗-话题@MedSci

#放化疗#

163篇内容 | 2050人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1287966, encodeId=adc3128e966a7, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JNCCN:老年局部肛管癌患者放化疗的不同应用比较, objectType=article, longId=212609, objectId=9198212609a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9198212609a8, replyNumber=0, likeNumber=37, createdTime=2021-06-13, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9198212609a8, moduleTitle=JNCCN:老年局部肛管癌患者放化疗的不同应用比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9198212609a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287965, encodeId=df93128e965ad, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Radiology:磁共振扩散峰度成像与人工智能的结合：预测直肠癌对新辅助放化疗的反应, objectType=article, longId=212585, objectId=10a321258526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10a321258526, replyNumber=0, likeNumber=25, createdTime=2021-06-12, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10a321258526, moduleTitle=Radiology:磁共振扩散峰度成像与人工智能的结合：预测直肠癌对新辅助放化疗的反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10a321258526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287964, encodeId=9159128e9646a, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=8, createdTime=2021-06-09, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287963, encodeId=d657128e96344, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=9, createdTime=2021-06-01, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287962, encodeId=352d128e9620c, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, objectType=article, longId=211907, objectId=ac0e21190e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0e21190e76, replyNumber=0, likeNumber=39, createdTime=2021-05-28, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0e21190e76, moduleTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0e21190e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287961, encodeId=a9e8128e96194, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , objectType=article, longId=211726, objectId=629e211e265b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629e211e265b, replyNumber=0, likeNumber=44, createdTime=2021-05-25, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629e211e265b, moduleTitle=Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629e211e265b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287960, encodeId=cffe128e96077, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet：PET-CT辅助前列腺癌术后放化疗可有效提高生存率！, objectType=article, longId=211384, objectId=cbc421138415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc421138415, replyNumber=0, likeNumber=31, createdTime=2021-05-17, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc421138415, moduleTitle=Lancet：PET-CT辅助前列腺癌术后放化疗可有效提高生存率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc421138415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287959, encodeId=d007128e95956, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新, objectType=article, longId=211196, objectId=ec7921119623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec7921119623, replyNumber=0, likeNumber=43, createdTime=2021-05-14, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec7921119623, moduleTitle=J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec7921119623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287958, encodeId=024c128e95851, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=210992, objectId=3d082109924e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d082109924e, replyNumber=0, likeNumber=25, createdTime=2021-05-10, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d082109924e, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d082109924e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287957, encodeId=b517128e957cf, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, objectType=article, longId=210515, objectId=4d42210515e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d42210515e4, replyNumber=0, likeNumber=35, createdTime=2021-04-28, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d42210515e4, moduleTitle=J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d42210515e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287956, encodeId=7c6f128e95635, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet Oncol：晚期直肠癌患者术前放化疗前予以强化化疗可进一步显著改善患者预后, objectType=article, longId=210478, objectId=b0512104e87b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0512104e87b, replyNumber=0, likeNumber=33, createdTime=2021-04-27, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0512104e87b, moduleTitle=Lancet Oncol：晚期直肠癌患者术前放化疗前予以强化化疗可进一步显著改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0512104e87b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287955, encodeId=14a2128e9551d, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, objectType=article, longId=210448, objectId=c74521044816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74521044816, replyNumber=0, likeNumber=30, createdTime=2021-04-27, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74521044816, moduleTitle=Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74521044816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287954, encodeId=82c7128e95488, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Int J Radiat Oncol Biol Phys：晚期胰腺癌适不适合放化疗，中性粒细胞计数有提示！, objectType=article, longId=209373, objectId=40f72093e392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40f72093e392, replyNumber=0, likeNumber=37, createdTime=2021-04-04, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40f72093e392, moduleTitle=Int J Radiat Oncol Biol Phys：晚期胰腺癌适不适合放化疗，中性粒细胞计数有提示！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40f72093e392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287953, encodeId=0dfb128e95358, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？, objectType=article, longId=208704, objectId=b07d208e046f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b07d208e046f, replyNumber=0, likeNumber=22, createdTime=2021-03-21, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b07d208e046f, moduleTitle=JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b07d208e046f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287952, encodeId=d8e2128e95240, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Br J Cancer：放化疗后HPV阳性口咽鳞状细胞癌中向肠道微生物组转变, objectType=article, longId=208295, objectId=0ec420829589, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec420829589, replyNumber=0, likeNumber=35, createdTime=2021-03-13, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec420829589, moduleTitle=Br J Cancer：放化疗后HPV阳性口咽鳞状细胞癌中向肠道微生物组转变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec420829589)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287951, encodeId=7452128e9515d, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Clin Cancer Res：肠道菌群可预测晚期直肠癌患者对新辅助放化疗的反应性！, objectType=article, longId=205962, objectId=580520596296, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=580520596296, replyNumber=0, likeNumber=31, createdTime=2021-01-22, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=580520596296, moduleTitle=Clin Cancer Res：肠道菌群可预测晚期直肠癌患者对新辅助放化疗的反应性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=580520596296)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287950, encodeId=e63c128e9504b, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, objectType=article, longId=205931, objectId=2ebe20593162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebe20593162, replyNumber=0, likeNumber=26, createdTime=2021-01-21, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebe20593162, moduleTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebe20593162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287949, encodeId=5007128e9497c, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Ann Oncol：3期| 胃癌的两种标准辅助化疗和一种标准放化疗的疗效PK！, objectType=article, longId=205892, objectId=43a7205892cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a7205892cc, replyNumber=0, likeNumber=46, createdTime=2021-01-21, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a7205892cc, moduleTitle=Ann Oncol：3期| 胃癌的两种标准辅助化疗和一种标准放化疗的疗效PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a7205892cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287948, encodeId=4029128e948a2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, objectType=article, longId=205784, objectId=6b89205e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b89205e84a3, replyNumber=0, likeNumber=44, createdTime=2021-01-17, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b89205e84a3, moduleTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b89205e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287947, encodeId=b828128e94759, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=8, createdTime=2020-09-26, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

放化疗

2020-05-29

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JNCCN:老年局部肛管癌患者放化疗的不同应用比较

2021-06-13

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Radiology:磁共振扩散峰度成像与人工智能的结合：预测直肠癌对新辅助放化疗的反应

2021-06-12

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-06-09

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2021-06-01

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果

2021-05-28

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet Oncology：局部晚期头颈肿瘤的放化疗：一项个体患者数据网状荟萃分析

2021-05-25

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet：PET-CT辅助前列腺癌术后放化疗可有效提高生存率！

2021-05-17

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Thorac Oncol：不可切除III期NSCLC放化疗后无进展患者德瓦鲁单抗（durvalumab）维持治疗4年生存分析结果：来自PACIFIC结果更新

2021-05-14

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-05-10

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Clin Oncol：震惊！局部晚期可切除的食管癌患者从术前放化疗中的生存获益可至少持续10年！

2021-04-28

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet Oncol：晚期直肠癌患者术前放化疗前予以强化化疗可进一步显著改善患者预后

2021-04-27

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Lancet oncol：多种放化疗联合方案治疗局部晚期头颈癌的疗效对比

2021-04-27

仁医06 (审核中...)

前往app查看评论内容

#放化疗#

Int J Radiat Oncol Biol Phys：晚期胰腺癌适不适合放化疗，中性粒细胞计数有提示！

2021-04-04

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Surg：局部晚期食管癌食管切除术前是新辅助放化疗还是新辅助化疗？

2021-03-21

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Br J Cancer：放化疗后HPV阳性口咽鳞状细胞癌中向肠道微生物组转变

2021-03-13

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Clin Cancer Res：肠道菌群可预测晚期直肠癌患者对新辅助放化疗的反应性！

2021-01-22

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）

2021-01-21

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Ann Oncol：3期| 胃癌的两种标准辅助化疗和一种标准放化疗的疗效PK！

2021-01-21

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效

2021-01-17

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2020-09-26

科室
- - 订阅+
  - 更多科室
工具
服务